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Background: Bacteremia by Streptococcus pneumoniae has been traditionally associated with poor outcomes in
patients with pneumonia; however, data on its impact on outcomes are limited and are sometimes contradictory.
Methods: We performed a prospective study in two hospitals in northern Spain in which cases diagnosed with
pneumococcal pneumonia were selected from a cohort of hospitalized patients with pneumonia between
January 2001 and July 2009. We compared patients with pneumococcal bacteremic pneumonia with those with
pneumococcal non-bacteremic pneumonia.
Results: We compared 492 patients with negative blood culture and 399 with positive culture results. Host related
factors were very similar in both groups. Severity of illness on admission measured by CURB-65 score was similar
in both groups. Adjusted analysis showed a greater likelihood of septic shock during in-hospital course among
patients with pneumococcal bacteremia (OR, 2.1; 95% CI, 1.2–3.5; P = 0.006). Likewise, patients with positive blood
culture had greater in-hospital mortality (OR 2.1; 95% CI, 1.1 − -3.9; P = 0.02), 15-day mortality (OR 3.6; 95% CI,
1.7 − 7.4; P = 0.0006), and 30-day mortality (OR, 2.7; 95% CI, 1.5 − 5; P = 0.002).
Conclusions: Although host related factors and severity on admission were very similar in the two groups,
bacteremic patients had worse in-hospital course and outcomes. Bacteraemia in pneumococcal pneumonia is of
prognostic significance.
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Despite the introduction of pneumococcal vaccination and
advances in antimicrobial agents, case-fatality rates among
adults with bacteremic pneumococcal pneumonia vary sig-
nificantly (ranging from 6% to 30%); they have improved
little in the past three decades and, in general, remain high
[1-6]. In addition, bacteremic pneumococcal pneumonia
continues to evolve, and regular comprehensive analysis of
this entity is necessary.
The severity of sepsis can be graded, using the American
Collage of Chest Physicians/Society of Critical Care Medi-
cine classification [7], into different progressive stages:
bacteremia, systemic inflammatory response syndrome
(SIRS), sepsis, severe sepsis, septic shock, and multiple* Correspondence: alberto.capelasteguisaiz@osakidetza.net
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article, unless otherwise stated.organ dysfunctions. Although there is a hierarchical
continuum of severity across sepsis, severe sepsis, septic
shock, and multiple organ dysfunction [8], the presence
of SIRS has no prognostic significance [9,10], and the
prognostic significance of bacteremia remains unclear.
Among patients with pneumonia, bacteremia due to
Streptococcus pneumoniae has traditionally been associ-
ated with poor outcomes, it being considered an inva-
sive form of infection. To date, however, there has been
little research on the impact of Streptococcus pneu-
moniae bacteremia on the outcome of pneumococcal
pneumonia: most studies have focused on bacteremic
infection [5,11-13], or on the impact of antibiotic resist-
ance on clinical outcome [14-16], few reports having
compared the clinical outcomes of pneumonia patients
with and without pneumococcal bacteremia. Moreover,
among the few existing comparative studies the findings
are contradictory and characteristics of some of theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of relatively small numbers of patients [17-20]; collec-
tion of information from a single institution [21,22];
and no adjusted analysis [17,23,24].
Our main objective was to assess whether bacteremia in
patients with pneumonia was related to severity on admis-
sion, septic shock at admission or during hospitalization,
and mortality in a large pneumococcal pneumonia study.
We hypothesized that the presence of bacteremia would
be associated with higher severity on admission, and also
higher rates of shock and mortality due to a greater degree
of systemic invasion.
Methods
Study population, design and setting
We analysed 4389 adult (18 years or older) patients hospi-
talized with pneumonia between January 2001 and July
2009. For this study, we selected patients diagnosed with
pneumococcal pneumonia and compared the subgroups
in this sample with bacteremic and non-bacteremic pneu-
monia. All patients with a diagnosis of pneumonia and at
least one positive blood culture for Streptococcus pneumo-
niae taken within 48 hours of presentation to the hospital
were included in the “pneumococcal bacteremic” group.
The “pneumococcal non-bacteremic” group included pa-
tients with positive Streptococcus pneumoniae antigen in
urine and negative blood cultures . Any individuals with
concurrent meningitis and/or endocarditis were excluded
from the analysis.
Data were collected prospectively from two hospitals
(Galdakao-Usansolo Hospital and Cruces University Hos-
pital) in the Basque Country (northern Spain). Galdakao-
Usansolo Hospital is a 400-bed general teaching hospital
serving a population of 300,000, while Cruces University
Hospital is a nearby large teaching hospital with a catch-
ment population of 400,000.
Patients were treated empirically with antibiotics ac-
cording to local practice guidelines: betalactam in com-
bination with macrolides, levofloxacin or betalactamics.
Medical care following discharge was determined by
patient's health-care providers. No interventions were
instigated as part of this study.
Study variables
All patients’ clinical and demographic characteristics
were recorded, as well as their vaccination status and
any previous antibiotic treatment for the current epi-
sode. To measure the severity of pneumonia upon
admission to the emergency department, we used the
CURB-65 (Confusion, Urea nitrogen, Respiratory rate,
Blood pressure, age ≥65 years) score [25].
Process-of-care variables included: 1) whether appro-
priate antibiotics were given (defined as an initial anti-
biotic treatment consistent with the recommendationsof Spanish Thoracic Society [SEPAR] [26]: third generation
cephalosporins or amoxicillin-clavulanic acid plus a macro-
lide, or levofloxacin in monotherapy for patients admitted
to a hospital ward; non-antipseudomonal cephalosporin
plus a macrolide, or levofloxacin instead of macrolide for
patients admitted to an intensive care unit)); and 2) and 3)
whether antibiotics were administered within 4 or within
8 hours of arrival at the emergency department, respect-
ively; as well as 4) length of antibiotic therapy; 5) length of
intravenous antibiotic therapy; and 6) the type of antibi-
otics given.
Clinical in-hospital measures included: whether the
patient 1) was admitted to the intensive care unit (ICU);
2) received mechanical ventilation; or 3) developed sep-
tic shock; as well as whether there was 4) treatment fail-
ure; or 5) severe sepsis.
Outcome measures included: 1) in-hospital mortality; 2)
and 3) mortality at 15 and 30 days after admission; 4) hos-
pital readmission within 30 days; and 5) length of hospital
stay (calculated as the date of discharge minus the date of
admission).
This study was approved by Galdakao Ethics Committee
and Cruces University Hospital Ethics Committee.
The formal consent to participate was verbal because
this study was not interventional.Definitions
Pneumonia was defined as pulmonary infiltrate on a
chest X-ray not known to have pre-existed and symp-
toms consistent with pneumonia, including cough, dys-
pnoea, fever, and/or pleuritic chest pain. Patients with
pneumonia were excluded if they were known to
be positive for human immunodeficiency virus, were
chronically immunosuppressed (defined as immuno-
suppression for solid organ transplantation, postsple-
nectomy, receiving ≥10 mg/day of prednisone or the
equivalent for more than 30 days, treatment with other
immunosuppressive agents, or neutropenia, i.e., <1.0 ×
109/L neutrophils), had been hospitalized for the previ-
ous 14 days before the diagnosis of pneumonia, or had
hospital-acquired pneumonia.
Septic shock was defined as systolic blood pres-
sure <90 mmHg and the need for vasopressors for
4 hours or more, while severe sepsis was defined as
sepsis associated with organ dysfunction and perfusion
abnormalities [27]. Treatment failure was defined as clinical
deterioration during hospitalization with hemodynamic
instability, confirmation of respiratory failure or the onset
thereof, the institution of mechanical ventilation, demon-
strated radiological progression of pneumonia or the ap-
pearance of a new focus of infection, or persistent fever or
the reappearance of fever if a change in treatment was
needed [28].
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The strategy for pneumococcal diagnosis included blood
cultures and a urinary antigen test during the first 24 hours
after arrival at hospital. The detection of Streptococcus
pneumoniae was performed by analysing concentrated
urine samples with an immunochromatographic mem-
brane assay (Binax Inc; Scarborough, ME). An etiologic
diagnosis of pneumococcal pneumonia was considered to
be definitive if one or both of the following criteria were
met: 1) isolation of Streptococcus pneumoniae in a sterile
specimen (blood and pleural fluid); and/or 2) positive
urinary antigen test for Streptococcus pneumoniae.
Statistical analysis
Descriptive statistics included frequency tables and mean
and standard deviation (SD). Patient characteristics,
process of care, in-hospital course and outcomes were
compared stratifying by blood culture result (positive vs.
negative). Chi-square and Fisher’s exact tests were per-
formed for the comparison of categorical variables, and
the Student’s t-test or nonparametric Wilcoxon tests
were performed for continuous variables.
Univariate logistic regression models were also used to
compare in-hospital course and outcomes between the
two groups of patients (unadjusted results). Then, multi-
variate logistic regression models were built for the com-
parison, adjusting for severity of illness at admission,
measured by CURB-65, as well as for patient characteris-
tics and variables related to the process of care found to
be significantly different in the groups stratified by blood
culture results. In the final multivariate models, only
adjusting variables found to be statistically significant were
kept. We determined odds ratios (ORs) and 95% confi-
dence intervals (95% CIs). For comparing lengths of hos-
pital stay, a general linear model was built, and due to the
skewed distribution of length of stay, the logarithmic
transformation was used.
Finally, Kaplan-Meier curves were constructed for 15-
and 30-day mortality for each group of patients, and com-
parisons were performed with the log-rank test. Further,
Cox proportional hazards model was used to compare sur-
vival between the two groups of patients adjusting for the
same variables as stated previously. We determined the
hazard ratios (HRs) and 95% CIs.
All effects were considered significant at P < 0.05. All
statistical analysis was performed using SAS for Windows,
version 9.2 (SAS Institute, Cary, NC) and S-Plus 2000
(MathSoft Inc., 1999).
Results
A total of 891 patients were identified in the study period
with a diagnosis of pneumococcal pneumonia and with
blood culture results. Pneumococcal bacteremia was iden-
tified in 399 (44.8%) cases. The group of pneumococcalnon-bacteremic pneumonia included 492 (55.2%) cases,
all of them with positive antigen in urine and negative
blood culture. The patient characteristics are summa-
rized in Table 1 by the blood culture result. Host-
related factors were very similar in the two groups,
although statistically significant differences were found
in sex, alcoholism, pneumococcal vaccine, congestive
heart failure, blood urea nitrogen and the radiological
findings on admission. Patients with positive blood cul-
tures had higher rates of bilateral or multilobe radio-
logical involvement and pleural effusion and were less
likely to have had the pneumococcal vaccine in the last
5 years. Severity of illness on admission measured by
the CURB-65 score was similar in the two groups. A
total of 395 (99.9%) of 399 blood isolates were available
for in vitro susceptibility testing. In nine (2.3%) cases,
pneumococci was highly resistant to penicillin (mini-
mum inhibitory concentration ≥ 4 μg/ml).
Process of care indicators in both groups are shown in
Table 2. Statistically significant differences were observed
in antibiotic management between the two groups. In par-
ticular, the use of antibiotics was appropriate according to
SEPAR guidelines in 85.3% of patients with negative cul-
tures and just 68.6% of those with positive cultures. In
both groups, however, over 90% of patients received anti-
biotics within 8 hours and the length of antibiotic therapy
was similar.
In-hospital course and outcome indicators in the two
groups are shown in Table 3 (unadjusted analysis). Pa-
tients with pneumococcal bacteremia had significantly
higher rates of mechanical ventilation use, septic shock
and treatment failure during the hospitalization, and
higher in-hospital, 15-day and 30-day mortality, as well
as longer hospital stays.
Table 4 shows the comparison of in-hospital course and
outcomes in the two groups adjusting for severity of ill-
ness at admission, measured by CURB-65, as well as for
patient characteristics and variables related to the process
of care found to be significantly different in the two
groups of patients, such as sex, congestive heart failure, al-
coholism, pneumococcal vaccine in last 5 years, pleural ef-
fusion, appropriate antibiotic, antibiotics within 4 hours,
dual antibiotic therapy including a macrolide, and anti-
biotic administration prior to hospital admission. A higher
likelihood of septic shock (OR, 2.1; 95% CI, 1.2 – 3.5; P =
0.006) during the hospital stay was found among patients
with pneumococcal bacteremia. Likewise, patients with
positive blood cultures had higher in-hospital mortality
(OR 2.1; 95% CI, 1.1 − 3.9; P = 0.02), 15-day mortality (OR,
3.6; 95%CI, 1.7 − 7.4; P = 0.0006), and 30-day mortality
(OR, 2.7; 95% CI, 1.5 − 5; P = 0.002). Kaplan-Meier survival
curves for each of the groups demonstrate markedly dif-
ferent survival trajectories in 15- and 30-day mortality
(Figure 1). Adjusted cox proportional hazards models
Table 1 Characteristics of patients hospitalized with









Age, years, mean (SD) 63.6 (18.5) 65.2 (17) 0.2
Age ≥65 years 225 (56.4) 290 (58.9) 0.4
Age >75 years 130 (32.6) 167 (33.9) 0.7
Women 131 (32.8) 210 (42.7) 0.003
Underlying diseases
Cancer 27 (6.8) 17 (3.5) 0.2
Liver disease 18 (4.5) 12 (2.4) 0.1
Congestive heart failure 54 (13.5) 43 (8.7) 0.02
Cerebrovascular disease 22 (5.5) 32 (6.5) 0.5
Renal disease 27 (6.8) 24 (4.9) 0.2
Chronic obstructive
pulmonary disease
74 (18.6) 116 (23.6) 0.07




0 203 (50.9) 253 (51.4)
1 130 (32.6) 156 (31.7)
≥2 66 (16.5) 83 (16.9)
Nursing home resident 13 (3.3) 20 (4.1) 0.5
Smoking 0.06
No 130 (43.5) 225 (47.8)
Yes 86 (28.8) 100 (21.2)
Ex-smoker 83 (27.8) 146 (31)
Alcoholism 58 (15.3) 44 (9.4) 0.008
Influenza vaccine in the last
year
93 (26.4) 149 (30.9) 0.2
Pneumococcal vaccine in
the last 5 years
14 (3.8) 121 (25.5) <0.0001
Findings on physical
examination on admission
Altered mental status 39 (9.8) 49 (10) 0.9
Pulse≥ 125/min 62 (15.6) 62 (12.6) 0.2
Respiratory rate≥ 30/min 98 (24.8) 96 (19.5) 0.06
Systolic blood pressure <
90 mmHg
30 (7.5) 42 (8.5) 0.6
Temperature < 35°C or ≥
40°C
7 (1.8) 4 (0.8) 0.2
Laboratory findings on
admission
Blood urea nitrogen >
30 mg/dL
192 (48.1) 163 (33.1) <0.0001
Glucose≥ 250 mg/dL 39 (9.8) 38 (7.7) 0.3
Hematocrit < 30% 10 (2.5) 23 (4.7) 0.1
Table 1 Characteristics of patients hospitalized with
pneumonia by Streptococcus pneumoniae by blood
culture result (Continued)
Sodium < 130 mmol/L 33 (8.3) 22 (4.5) 0.02
PaO2 < 60 mmHg 188 (47.1) 209 (42.5) 0.2





142 (35.7) 122 (24.8) 0.0004
Pleural effusion 65 (16.3) 43 (8.7) 0.0006
Severity of illness on
admission
CURB65 score* 0.07
0,1 145 (36.3) 215 (43.7)
2 159 (39.9) 167 (33.9)
>2 95 (23.8) 110 (22.4)
SD, standard deviation.
Data are expressed as numbers (percentage) unless otherwise stated.
Percentages exclude patients with missing data.
*Severity of illness on admission assessed with CURB-65 (Confusion, Urea
nitrogen, Respiratory rate, Blood pressure, age ≥65 years) score.
Table 2 Process-of-care of patients hospitalized with









Previous antibiotic treatment 26 (6.5) 56 (11.4) 0.013
Appropriate antibiotic* 273 (68.6) 419 (85.3) <0.0001
Antibiotics within 4 hours 257 (73) 389 (79.7) 0.019
Antibiotics within 8 hours 330 (93.8) 471 (96.5) 0.06
Length of antibiotic therapy,
days, mean (SD)†
14.7 (7.2) 13.9 (4.6) 0.9
Length of intravenous antibiotic
therapy, days, mean (SD)†
7 (7.2) 5.9 (4.8) 0.4
Antibiotic treatment <0.0001
Beta-lactam monotherapy 93 (23.4) 113 (23)
Beta-lactam/macrolide 13 (3.3) 30 (6.1)
Fluoroquinolones 257 (64.6) 346 (70.5)
Macrolide monotherapy 1 (0.3) 0 (0)
Others 34 (8.5) 2 (0.4)
Dual antibiotic therapy
including a macrolide
13 (3.3) 31 (6.3) 0.037
SD, standard deviation.
Data are given as number (percentage) unless otherwise indicated.
The percentage excluded patients with missing data.
*Appropriate antibiotic defined as usage of antibiotics recommended in the
guidelines of the SEPAR.
†Deaths are excluded.
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Table 3 In-hospital course and outcomes of patients hospitalized with pneumonia by Streptococcus pneumoniae by
blood culture result




P value Odds ratio (95% CI)
In-hospital course
Admission to intensive care unit 92 (23.1) 101 (20.5) 0.4 1.2 (0.8 – 1.6)
Need for mechanical ventilation 42 (10.5) 27 (5.5) 0.005 2 (1.2 – 3.4)
Septic shock* 53 (14.9) 33 (6.7) 0.0001 2.4 (1.5 – 3.8)
Treatment failure 72 (18.2) 59 (12.1) 0.01 1.6 (1.1 – 2.3)
Severe sepsis 185 (46.4) 203 (41.3) 0.1 1.2 (0.9 – 1.6)
Outcomes
In-hospital mortality 35 (8.8) 22 (4.5) 0.009 2.1 (1.2 – 3.6)
15-day mortality 33 (8.3) 14 (2.9) 0.0003 3.1 (1.6 – 5.8)
30-day mortality 37 (9.3) 18 (3.7) 0.0005 2.7 (1.5 – 4.8)
30-day readmission 10 (3.3) 27 (5.6) 0.1 0.6 (0.3 – 1.2)
Length of hospital stay (days)†
Mean (SD) 10 (13.7) 7 (5.5) 0.02 1.2 (1.04 – 1.3)║
Median (IRQ) 6 (4 – 10) 6 (4 – 8) 0.02
>3 days 295 (81) 373 (79.4) 0.5 1.1 (0.8 – 1.6)
SD, standard deviation; CI, Confidence interval; IRQ, Interquartile range.
Data are given as number (percentage) unless otherwise indicated. Percentages exclude patients with missing data. Treatment failure is defined in the text.
*Septic shock is defined as arterial systolic blood pressure <90 mm Hg and the need for vasopressors for a minimum of 4 hours.
†Deaths are excluded.
║For the comparison of length of hospital stay as a continuous variable, the general linear model was used, and due to the skewed distribution of length of stay,
the logarithmic transformation was applied. Hence, data are given as the exponential of the estimated beta parameter, indicating how many times longer the
length of stay was among blood culture-positive than culture-negative patients with Streptococcus pneumoniae.
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the two groups of patients: for 15-day mortality, the HR
was 3.3 (95% CI, 1.7 − 6.5, P = 0.0005); and for 30-day
mortality, the HR was 2.8 (95% CI, 1.6 − 5.1, P = 0.0006).
Discussion
Our findings confirm that there are substantial differ-
ences in in-hospital course and outcomes among pa-
tients hospitalized with pneumonia due to Streptococcus
pneumoniae as a function of their blood culture results.
We found that patients with pneumococcal bacteremia
have a poorer in-hospital course – in terms of septic
shock – and poorer outcomes – in terms of in-hospital,
15- and 30-day mortality. Notably, we also identified that
the illness severity on admission assessed by CURB-65
score was similar in the two groups.
Our study is important as comparing bacteremic with
non-bacteremic pneumoccocal pneumonia we have iden-
tified that both course and outcomes are poorer for
bacteremic patients while they show a similar severity of
illness on admission. There is one previous study with the
same design and similar results; the differences observed in
the mortality were not, however, adjusted for host-related
factors or antibiotic treatment [18]. Others strengths of this
study are its prospective design, identification of cases
based on clinical diagnosis, relatively large sample of non-selected patients, comprehensive assessment of outcomes,
detailed collection of clinical data, and use of a robust risk-
adjustment model.
When comparing characteristics of two groups of
patients, the similarities rather than the differences are ini-
tially what are most important. In our study, patients were
similar in age, level of comorbidity, and severity of illness
on admission. Observed gender differences are consistent
with the results of other studies [29,30], suggesting that
women are less likely to develop sepsis, maybe related to
the sex hormones or anatomic, lifestyle and behavioural dif-
ferences [31]. Blood urea nitrogen, higher in bacteremic pa-
tients group, is an independent variable associated with the
severity of pneumonia [25]. The dehydration, which is com-
mon in older patients hospitalized for pneumonia [32], may
also contribute to a higher urea level. Besides, the rate of
bilateral or multilobe radiological involvement and pleural
effusion were significantly higher in bacteremic patients.
Our findings indicate that the bacteremic patients had a
poorer prognosis and higher case-fatality rate, while the
illness severity on admission was similar in the two groups
as assessed by the CURB-65 score. It is possible that
bacteremic pneumococcal pneumonia adds some features
that are not captured by this severity score.
The fact that clinical outcomes of pneumonia patients
are different depending on whether or not they have
Table 4 Comparison between in-hospital course and
outcomes of patients hospitalized with pneumonia by
Streptococcus pneumoniae according the blood culture
results: adjusted analysis
Odds ratio (95% CI)* P Value
In-hospital course
Admission to intensive care unit 1 (0.7 – 1.4) 0.8
Use of mechanical ventilation 1.7 (1 – 3.1) 0.06
Septic shock† 2.1 (1.2 – 3.5) 0.006
Treatment failure 1.4 (1 – 2.1) 0.06
Severe sepsis 1.1 (0.8 – 1.5) 0.4
Outcomes
In-hospital mortality 2.1 (1.1 – 3.9) 0.02
15-day mortality 3.6 (1.7 – 7.4) 0.0006
30-day mortality 2.7 (1.5 – 5) 0.002
30-day readmission 0.5 (0.2 – 1.1) 0.08
Length of hospital stay (days)‡
Continuous 1.1 (1 – 1.2)║ 0.1
>3 days 1 (0.7 – 1.4) 0.8
CI, confidence interval.
*Odds ratio adjusted by severity of illness on admission measured by CURB-65,
and those characteristics of patients and variables related to process-of-care
which were found statistically significant according to blood culture results,
such as sex, congestive heart failure, alcoholism, pneumococcal vaccine in
last 5 years, pleural effusion, appropriate antibiotic, antibiotics within 4 hours,
dual antibiotic therapy including a macrolide, and antibiotic administration
prior to hospital admission. Only significant adjusting variables were kept in
each model.
†Septic shock defined as arterial systolic blood pressure <90 mm Hg and need
for vasopressors ≥ 4 hours.
‡Deaths are excluded.
║For the comparison of length of hospital stay as a continuous variable, the
general linear model was used, and due to the skewed distribution of length
of stay, the logarithmic transformation was applied. Hence, data are given as
the exponential of the estimated beta parameter, indicating how many times
longer the length of stay was among blood culture-positive than culture-
negative patients with Streptococcus pneumoniae.

























Figure 1 Kaplan-Meier survival curves for the blood culture positive a
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issue that has yet to be fully understood. Our study adds
new data on this issue in that it shows that the bacteremia
is associated with poorer in-hospital course and outcomes.
There are previous studies [17-20] with contradictory find-
ings, although all of these have a small sample size without
the adequate power to detect outcome differences between
bacteremic and non-bacteremic groups of patients.
In agreement with our findings, several studies [14,
21,22,24] have found that bacteremia is a risk factor
for death in patients with pneumonia. A meta-analysis
[24] identified 11 factors, including bacteremia, with
statistically significant associations with mortality in
patients with pneumonia; however, the authors were
unable to determine whether these factors are inde-
pendently associated with mortality due to the nature of
the primary data. Garcia-Vidal et al. [21], in a study car-
ried out in a single hospital, identified pneumoccocal
bacteremia as an independent factor associated with
early death in patients with pneumonia. Further, a re-
cent study [22] performed in one hospital in Taiwan
found that the presence of Streptococcus pneumoniae
bacteremia predicted mortality in pneumococcal pneu-
monia, although these authors included immunosup-
pressed patients and children. In contrast to our study,
however, a Canadian multicentre study [23] showed
similar outcomes in bacteremic pneumococcal pneu-
monia and non-bacteremic pneumonia, though using
non-adjusted analysis. The low mortality rate (of 5.3%)
among patients with pneumococcal bacteremia in that
study is attributable to the fact that the most severely
ill patients were often not enrolled. An international,
retrospective study [33] concluded that pneumococcal
bacteremia does not increase the risk of poor outcomes in
patients with pneumonia; ICU admission rate and the
non-adjusted pneumonia-mortality were, however, signifi-
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patients with pneumonia admitted to the ICU, bacteremia
was not found to affect outcomes: in this case, the results
may be due in part to enrolment bias, because the re-
quirements for ICU admission in Spain have a selective
approach for patients with advanced age and chronic
risk factors.
Although we have assessed the differences in mortal-
ity between bacteremic and non-bacteremic groups
adjusting for the antibiotic treatment used, the prescrip-
tion of an antibiotic was appropriate according SEPAR
guidelines in less than 70% of cases in the bacteremic
group, because of the use of beta-lactam antibiotics
alone. This treatment may be considered suboptimal
because previous research [35,36] suggests a benefit of
combination therapies, including a macrolide, applied
to pneumonia associated with Streptococcus pneumo-
niae bacteremia. On the other hand, these studies are
hampered by design limitations, and their conclusions
should be interpreted with caution [37].
A potential weakness should be noted. In the current
study, the ratio of bacteremic to non-bacteremic epi-
sodes was 81.1% (399/492 patients) when the percentage
of patients with pneumococcal pneumonia and positive
blood culture does not usually exceed 30%. In this study,
only cases with blood culture results were included. The
number of diagnosed cases of pneumococcal pneumonia
was higher during the study period. This was due to the
fact that requests for blood cultures in pneumonia are
optional and depend on the judgment of the attending
physician. In fact, it is accepted clinical practice not to
request a blood culture once an immediate diagnosis has
been obtained by the urinary antigen test. An another
question to take into account. Inclusion criteria for
“pneumococcal non-bacteremic” group were stringent in
order to achieve an unquestionable diagnosis. Only the
patients with positive antigen in urine and negative
blood culture were included in this group. For this study
we excluded patients whose diagnosis was just based on
sputum culture, because a diagnosis method of pneumo-
coccal pneumonia that does not depend on sputum cul-
ture is desirable.
Conclusions
We have examined the differences in pneumococcal pneu-
monia as a function of blood culture results. Although the
host-related factors and severity on admission were very
similar in the two groups, bacteremic patients had a poorer
in-hospital course and outcomes. Bacteremia in pneumo-
coccal pneumonia has prognostic significance given that is
associated with poorer outcomes.
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